BioNTech SE
Financial Performance
BioNTech Revenue & Financials
Revenue
~$3.2B (FY2025)
Market Cap
$24.7B
Employees
7,807
What is BioNTech's revenue?
BioNTech had ~$3.2B in revenue for fiscal year 2025, up 4.3% from 2024. It reported a net loss of ~$1.3B.
- Latest revenue
- ~$3.2B (FY2025)
- Year-over-year
- +4.3%
- Growth rate (CAGR)
- 61.6% over 8 years
- Peak revenue
- ~$21.4B (FY2021)
- Years of data
- 9
- Employees
- 7,807
- How much profit does BioNTech make?
- BioNTech reported a net loss of ~$1.3B for fiscal year 2025. sec.gov
- How many employees does BioNTech have?
- BioNTech has about 7,807 employees.
Financial Analysis
BioNTech went from a ~$202 million (€179.1 million) net loss in 2019 to ~$11.6 billion (€10.29 billion) of net profit on ~$21.4 billion (€18.98 billion) of revenue in 2021, almost all from Comirnaty. Revenue then fell to ~$19.6 billion (€17.31 billion) in 2022, ~$4.32 billion (€3.82 billion) in 2023 and ~$3.11 billion (€2.75 billion) in 2024, when it posted a ~$752 million (€665.3 million) net loss. FY2025 revenue rose 4.3% to ~$3.24 billion (€2.87 billion) only because BMS collaboration revenue was booked in Q3, while the net loss widened to ~$1.29 billion (€1.14 billion) on ~$2.37 billion (€2.10 billion) of R&D and legal settlement costs. In 2026 the decline resumed: H1 revenue fell to ~$253 million (€223.7 million), the H1 net loss reached ~$1.53 billion (€1.35 billion), and full-year revenue guidance was cut to €1.6-1.9 billion. The cushion is ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, which also funds a $1.0 billion ADS buyback launched in May 2026. BioNTech skyrocketed in value during the global pandemic, maintaining a market valuation generally exceeding $20 billion driven by its mRNA pipeline.
Revenue Trend Analysis
YoY Change
+4.3%
8-Year CAGR
+61.6%
Peak Year
2021
Trend
Mostly Growing
BioNTech SE has 9 full fiscal year figures on this page, compounding at +61.6% annually over 8 years. The most recent year saw a 4.3% increase versus the prior year. Annual revenue peaked in fiscal year 2021 at ~$21.4B. Of 8 comparable year-over-year steps, 4 showed growth and 4 showed a decline.
Annual revenue history
Click any row to see year details.
BioNTech SE balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 20-F, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | ~$515.3M | ~$197.9M | ~$24.8B | ~$3.1B | — | ~$317.4M | Form 20-F |
| FY2024ended Dec 31, 2024 | ~$234.7M | ~$323.7M | ~$25.5B | ~$3.5B | — | -~$89M | Form 20-F |
| FY2023ended Dec 31, 2023 | ~$6.1B | ~$281.8M | ~$26B | ~$3.1B | — | ~$5.8B | Form 20-F |
| FY2022ended Dec 31, 2022 | ~$15.3B | ~$372M | ~$26.3B | ~$3.6B | — | ~$15B | Form 20-F |
| FY2021ended Dec 31, 2021 | ~$1B | ~$144.1M | ~$17.9B | ~$4.4B | — | ~$861.3M | Form 20-F |
| FY2020ended Dec 31, 2020 | -~$15.3M | ~$74.6M | ~$2.6B | ~$1.1B | — | -~$89.8M | Form 20-F |
| FY2019ended Dec 31, 2019 | -~$224.3M | ~$43.6M | ~$901.3M | ~$343.7M | ~$557.6M | -~$267.9M | Form 20-F |
| FY2018ended Dec 31, 2018 | -~$66.5M | ~$33.8M | ~$737.9M | ~$436.2M | ~$300.8M | -~$100.3M | Form 20-F |
Keep researching BioNTech
BioNTech Revenue and Financial FAQ
How much did BioNTech earn at the peak of the pandemic?
BioNTech reported revenue of ~$21.4 billion (€18.98 billion) and net profit of ~$11.6 billion (€10.29 billion) in 2021, followed by ~$19.6 billion (€17.31 billion) of revenue and ~$10.7 billion (€9.43 billion) of net profit in 2022, almost all from Comirnaty.
What were BioNTech's 2025 financial results?
FY2025 revenue was ~$3.24 billion (€2.87 billion), up 4.3% from ~$3.11 billion (€2.75 billion) in 2024 because of BMS collaboration revenue. The net loss widened to ~$1.29 billion (€1.14 billion) (diluted loss of €4.70 per share), and R&D expenses were ~$2.37 billion (€2.10 billion).
How much cash does BioNTech have?
BioNTech held ~$18.8 billion (€16.63 billion) in cash, cash equivalents and security investments on June 30, 2026, down from ~$19.5 billion (€17.24 billion) on December 31, 2025.
How much does BioNTech spend on R&D?
R&D expenses were ~$2.54 billion (€2.25 billion) in 2024 and ~$2.37 billion (€2.10 billion) in 2025. For 2026, BioNTech guides adjusted R&D of €2.0-2.3 billion, lowered in August 2026 from €2.2-2.5 billion.
Does BioNTech buy back shares?
Yes. In May 2026 BioNTech started a program to repurchase up to $1.0 billion of ADSs through May 6, 2027, and bought 1,693,056 ADSs for $151.6 million in Q2 2026.
What is BioNTech's 2026 revenue guidance?
In August 2026 BioNTech cut its 2026 revenue guidance to €1.6-1.9 billion from €2.0-2.3 billion, citing softer COVID-19 vaccine demand and milestone revenue that slipped out of 2026. It expects most 2026 revenue in Q3, including ~$693 million (€613 million) of BMS collaboration revenue.
How did BioNTech pay for its recent acquisitions?
Biotheus cost $800 million, mostly in cash, plus up to $150 million in milestones. CureVac was acquired in an all-stock exchange offer that closed in December 2025.
What is BioNTech's market cap?
Stock Analysis put BioNTech's market capitalization at $24.69 billion on September 30, 2026, with an enterprise value of $9.67 billion because most of its value is backed by cash and securities.
Is BioNTech profitable?
Yes, the company generated absolutely staggering, unprecedented profits (tens of billions of dollars) during the peak of the pandemic, giving them a massive cash hoard to fund future R&D for decades.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "BioNTech Revenue & Financials." CorpDigest, https://corpdigest.com/company/biontech/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>BioNTech reported ~$3.2B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/biontech/financials" target="_blank" rel="noopener">CorpDigest — BioNTech financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore BioNTech
Core profile pages, founders and related research hubs for this company.